Stock Market Navigation_Dec 10, 2025_Announcements and Trading Tips for Shanghai and Shenzhen Markets

Deep News12-10

【M&A Restructuring】 - Borui Communications: Plans to acquire 51% stake in Meijing Technology for CNY 66.49 million. - Xiamen Airport: Plans to acquire 100% stake in Zhaoxiang Technology, a subsidiary of its controlling shareholder. - Tianyouwei: Plans to purchase 100% stake in Kramer Automotive Systems Ltd. for EUR 1 million.

【Hotspots】 - Longzhou Co., Ltd. (5 consecutive limit-ups): Clarifies no involvement in commercial aerospace business. - Shengxing Co., Ltd. (3 consecutive limit-ups): Currently planning private share issuance. - Bona Film Group (2 consecutive limit-ups): Low investment return ratio for "Avatar 3" with no significant short-term impact. - Daye Co., Ltd.: Invested Jiangbei Co. focuses on aerospace R&D; current net profit remains modest. - Yifang Biotech: Plans H-share issuance and listing on HKEX. - LONGi Green Energy: Terminates overseas GDR issuance.

【Equity Changes】 - Zaisheng Technology: Controlling shareholder Guo Mao plans to transfer 6.04% stake via agreement. - Jiuzhitang: China National Pharmaceutical Investment to acquire 5% stake. - Jiamei Packaging: Controlling shareholder plans change of control; trading halted. - Guao Technology (Rights Protection): Actual controller plans change of control; trading remains suspended. - Haimo Technology: Plans to sell entire stake in subsidiary Sitan Instruments. - Layn Natural Ingredients: Plans control change and asset acquisition; trading halted from Dec 10. - Fulede: Plans to transfer 4.1 million shares in Haigude, expecting CNY 180 million investment gain.

【Shareholding Changes & Buybacks】 - HuiTai Medical: Plans CNY 200–250 million share buyback. - Songcheng Performance: Plans CNY 100–200 million share buyback. - Impulse Fitness: Controlling shareholder plans CNY 60–120 million share purchase. - Jingu Holdings: Plans CNY 30–60 million share buyback. - Financial Street: Hexie Health recently acquired 7.04 million shares. - Aokang International (Rights Protection): Shareholder plans ≤3% stake reduction. - Digital China: Controlling shareholder plans ≤3% stake reduction. - Kutesmart: Controlling shareholder’s concerted parties plan ≤2% stake reduction. - Donghua Testing: Controlling shareholder and concerted parties plan ≤1.99% stake reduction. - Lixin New Energy: Shareholder Shandong Electric Power plans ≤1% stake reduction.

【Operating Data】 - China Life Insurance: Total premiums exceed CNY 700 billion as of Nov 30, 2025. - China Merchants Shekou: November contracted sales reach CNY 14.09 billion. - Shouqi Co., Ltd. (Rights Protection): Jan–Nov contracted sales total CNY 15.99 billion. - New Wufeng: November hog sales hit 575,500 heads, up 80.97% YoY. - Zhengbang Technology: November hog sales revenue rises 8.55% MoM to CNY 741 million. - Luoniushan: November hog sales revenue up 13.57% YoY to CNY 111 million. - Tiankang Biology: November hog sales revenue grows 1.2% MoM to CNY 420 million. - Tangrenshen: November hog sales revenue drops 24.05% MoM to CNY 629 million. - Shenzhen Airport: November passenger throughput up 8.77% YoY.

【Contracts & Bids】 - Chongqing Construction: Subsidiary wins CNY 1.71 billion construction project. - Jinggong Technology: Signs CNY 729 million sales contract with Hubei Yuchuang. - *ST Weihai (Rights Protection): Wins CNY 652 million Luoping smart agriculture project. - Jingce Electronics: Signs multiple contracts totaling CNY 433 million with same client over 12 months. - Heshun Electric: Pre-wins CNY 107 million State Grid tender. - Wanma Technology: Pre-wins CNY 59.94 million State Grid projects. - Zhongchao Holdings: Subsidiary secures CNY 51.56 million high-temperature alloy casting order. - Biointelli Technology: Pre-wins core mold tooling projects totaling CNY 27.5 million.

【Major Investments】 - Tiandi Technology: Plans R&D center for intelligent coal mining equipment. - Longjiang Transportation: Subsidiary to invest CNY 2.68 billion in 2M-ton graphite mining project. - Xingfu Electronics: Plans CNY 480 million electronic-grade phosphoric acid project. - Yongmaotai: Plans ~CNY 400 million Mg-Al alloy auto/robot parts project. - Tongyizhong: Plans ~CNY 198 million UHMWPE fiber project (2,400 tons/year).

【Others】 - Shuangta Food: Thai subsidiary production line operational. - Boyuan Chemical: Subsidiary’s Alashan Tamusu natural alkali project begins trial run. - Guangdong Electric Power: Unit 3 of Dapu Power Plant Phase II operational. - Hisoar Pharmaceutical: Partners with Hangzhou Advanced Research Institute for synthetic tech lab. - Huayi Group: Subsidiary Wanhao Co. halts production for environmental upgrades. - Zhangyue Technology: Receives CNY 4.99 million dividend from Dianzhong Technology. - LONGi Green Energy: Terminates overseas GDR issuance. - Tiandike: Chairman Chen You under investigation. - Yangfan New Materials: Controlling shareholder Fan Peiren released from investigation. - Nanhua Futures: Overseas subsidiary approved as Coinbase Derivatives member. - *ST Kaiwen: Other risk警示 lifted from Dec 11. - 3Peak: Terminates acquisition of Aura shares; trading resumes tomorrow. - Zhonghong Medical: Subsidiary product pre-selected for bulk procurement. - Fosun Pharma: Subsidiary signs licensing agreement with Pfizer. - Xingqi Eye Pharma: Completes first patient enrollment for SQ-22031 dry eye Phase II trial. - Dizal Pharma: Releases Gaoruizhe® and Birelentinib data at 67th ASH. - Dongcheng Pharmaceutical: Subsidiary’s dalteparin sodium injection approved for new specification. - *ST Nuotai (Rights Protection): Atosiban acetate injection approved. - Yuandong Bio: Brexpiprazole tablets approved. - New Industries: Medical device registration obtained. - Tiance Pharma: Subsidiary’s methimazole tablets approved. - Xianju Pharma: Nicardipine hydrochloride injection passes generic consistency evaluation. - Jiudian Pharmaceutical: JMHT06 clinical trial approved. - Xintiandi: Ferrous fumarate API approved. - Kehua Bio: Subsidiary’s medical device registration obtained. - David Medical: Subsidiary obtains 2 medical device registrations. - Fujilai: Lipoic acid tablets approved.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment